Application of albiflorin as indoleamine 2,3-dioxygenase (ido) inhibitor

Use of albiflorin or a pharmaceutically acceptable salt thereof, or an extract containing albiflorin or a pharmaceutically acceptable salt thereof in the preparation of a drug, a food, a health care product, a food additive or a nutritional supplement for inhibiting the activity of IDO.

Use of albiflorin or a pharmaceutically acceptable salt thereof, or an extract containing albiflorin or a pharmaceutically acceptable salt thereof in the preparation of a drug, a food, a health care product, a food additive or a nutritional supplement for the prevention or treatment of a disease having a pathological feature involving tryptophan metabolic pathway mediated by overactivation of IDO;

• preferably, the disease is selected from one or more of AIDS, cancer, neurodegenerative disease, depression, cataract, age-related yellowing, and autoimmune disease;
• more preferably, the neurodegenerative disease is selected from one or more of Alzheimer's disease, Huntington's disease and Parkinson's disease;
• further preferably, the drug is a drug used for the immunotherapy of cancer.

Use of albiflorin or a pharmaceutically acceptable salt thereof, or an extract containing albiflorin or a pharmaceutically acceptable salt thereof in the preparation of a drug, a food, a health care product, a food additive or a nutritional supplement for the prevention or treatment of inflammatory depression, post-stroke depression (PSD), depressive disorder accompanied with somatopathy such as cancer, hepatitis, nephritis, etc., stroke accompanied with inflammation, Alzheimer's disease accompanied with inflammation, or Parkinson's disease accompanied with inflammation.

A method for inhibiting overactivation of IDO, comprising administration of a therapeutically effective amount of albiflorin or a pharmaceutically acceptable salt thereof, or an extract containing albiflorin or a pharmaceutically acceptable salt thereof.

A method for the prevention or treatment of a disease having a pathological feature involving tryptophan metabolic pathway mediated by overactivation of IDO, comprising administration of a therapeutically effective amount of albiflorin or a pharmaceutically acceptable salt thereof, or an extract containing albiflorin or a pharmaceutically acceptable salt thereof;

• preferably, the disease is selected from AIDS, cancer, neurodegenerative disease, depression, cataract, age-related yellowing, and autoimmune disease;
• more preferably, the neurodegenerative disease is selected from one or more of Alzheimer's disease, Huntington's disease and Parkinson's disease;
• further preferably, the method is the immunotherapy of cancer.

A method for the prevention or treatment of inflammatory depression, post-stroke depression (PSD), depressive disorder accompanied with somatopathy such as cancer, hepatitis, nephritis, etc., stroke accompanied with inflammation, Alzheimer's disease accompanied with inflammation, or Parkinson's disease accompanied with inflammation, comprising administration of a therapeutically effective amount of albiflorin or a pharmaceutically acceptable salt thereof, or an extract containing albiflorin or a pharmaceutically acceptable salt thereof.

A composition for inhibiting IDO, comprising albiflorin or a pharmaceutically acceptable salt thereof, or an extract containing albiflorin or a pharmaceutically acceptable salt thereof;

• preferably, the composition is a drug, a food, a health care product, a food additive or a nutritional supplement.

A composition for the prevention or treatment of inflammatory depression, post-stroke depression (PSD), depressive disorder accompanied with somatopathy such as cancer, hepatitis, nephritis, etc., stroke accompanied with inflammation, Alzheimer's disease accompanied with inflammation, or Parkinson's disease accompanied with inflammation, comprising albiflorin or a pharmaceutically acceptable salt thereof, or an extract containing albiflorin or a pharmaceutically acceptable salt thereof.